Bioatla

$10.82 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Bioatla

BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

Stock Analysis

last close $11.04
1-mo return -44.6%
3-mo return -60.2%
avg daily vol. 496.97T
52-week high 76.63
52-week low 11.04
market cap. $446M
forward pe -
annual div. -
roe -113.2%
ltg forecast -
dividend yield -
annual rev. $0M
inst own. 72.8%
baraka

Subscribe now for daily local and international financial news

Subscribe